The filing is a routine quarterly update with no surprise — the widening loss was expected given the active Phase III trial. The key catalyst remains MAVERIC topline data, expected in H2 2026. Monitor enrollment updates and any partnership announcements. The stock is a binary event play on Phase III results; position sizing should reflect that risk.
Price Chart
Executive Summary
Cardiol Therapeutics reported Q1 2026 results: net loss widened to C$10.8M from C$8.3M a year ago, driven by higher R&D spend (C$4.9M vs C$3.8M) and a C$1.5M non-cash derivative liability charge. Cash burn from operations was C$7.5M, but the January 2026 unit offering added C$14.9M gross, leaving cash at C$27.7M. The Phase III MAVERIC trial in recurrent pericarditis is 75% enrolled with target completion expected by Q3 2026. The widening loss and absence of revenue keep the stock in a binary catalyst wait — MAVERIC results are the key event.
Key Facts
- Net loss for Q1 2026 was C$10,818,589 vs C$8,287,653 in Q1 2025, a 30.5% increase.
- R&D expense rose to C$4,949,411 from C$3,757,412, driven by MAVERIC (C$2.3M) and CRD-38 (C$0.8M) programs.
- Cash and cash equivalents were C$27,673,191 as of March 31, 2026, up from C$21,416,684 at year-end 2025.
- Cash used in operations was C$7,517,631 for Q1 2026 vs C$7,153,767 in Q1 2025.
- In January 2026, the company completed a unit financing for gross proceeds of C$14,850,001, issuing 11,423,078 units at C$1.30 each.
- Phase III MAVERIC trial enrollment reached 75% as of April 2026; target recruitment anticipated by end of Q2 or Q3 2026.
- The company expects existing cash to fund operations into Q4 2027.
- Basic and diluted loss per share was C$0.10, unchanged from Q1 2025, on a higher weighted-average share count of 108,987,584 (vs 82,608,992).
Financial Impact
Net loss increased by C$2.5M YoY; cash burn from operations was C$7.5M for the quarter; cash runway extended into Q4 2027 via C$14.9M January offering.
Risk Factors
- Phase III MAVERIC trial may fail to meet its primary endpoint, eliminating the near-term catalyst.
- Cash runway into Q4 2027 assumes no cost overruns; additional dilutive financing may be needed if MAVERIC results are delayed or negative.
- No revenue and history of operating losses; the company is entirely dependent on clinical success and future financing or partnerships.
- Significant dilution from outstanding warrants (11.4M), options (4.8M), PSUs (3.5M), and RSUs (4.8M) overhangs the stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-058766 |
| Document: tm2614096d1_ex99-2.htm | 0001104659-26-058766 |
| Document: tm2614096d1_6k.htm | 0001104659-26-058766 |
| Document: tm2614096d1_ex99-4.htm | 0001104659-26-058766 |
| Document: tm2614096d1_ex99-3.htm | 0001104659-26-058766 |
| Document: 0001104659-26-058766-index-headers.html | 0001104659-26-058766 |
| Document: 0001104659-26-058766-index.html | 0001104659-26-058766 |
| Document: 0001104659-26-058766.txt | 0001104659-26-058766 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.15 (−34.75%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.15 (−34.75%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.15 (−39.21%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.11%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.11%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.15 (−49.45%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.15 (−13.81%) |
Jul 14, 2026 15w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.15 (+0.43%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.15 (+16.43%) |
May 26, 2026 22w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.15 (−11.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers